Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Among authors: larosa m. Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):1846-1853. doi: 10.1016/j.numecd.2024.03.023. Epub 2024 Mar 23. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036 Free article.
Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population.
Bonadonna RC, Giaccari A, Buzzetti R, Aimaretti G, Cucinotta D, Avogaro A, Perseghin G, Larosa M, Bolli GB, Fanelli CG. Bonadonna RC, et al. Among authors: larosa m. Nutr Metab Cardiovasc Dis. 2019 May;29(5):496-503. doi: 10.1016/j.numecd.2019.01.011. Epub 2019 Feb 8. Nutr Metab Cardiovasc Dis. 2019. PMID: 30952575 Clinical Trial.
Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study.
Ragonese M, Larosa M, Angotti S, Annese S, Cruciani L, Dainelli M, Lucisano G, Prosperini G, Sacco M, Salomone E, Saponara C, Semprini R, Rossi MC, Nicolucci A. Ragonese M, et al. Among authors: larosa m. Diabetes Ther. 2020 Oct;11(10):2283-2298. doi: 10.1007/s13300-020-00902-1. Epub 2020 Aug 19. Diabetes Ther. 2020. PMID: 32813262 Free PMC article.
Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY).
Fadini GP, Buzzetti R, Nicolucci A, Larosa M, Rossi MC, Cucinotta D; RESTORE-2 Study Group. Fadini GP, et al. Among authors: larosa m. Acta Diabetol. 2022 Oct;59(10):1317-1330. doi: 10.1007/s00592-022-01925-9. Epub 2022 Jul 21. Acta Diabetol. 2022. PMID: 35864262 Free PMC article.
Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.
Candido R, Modugno M, Larosa M, Rossi MC, Nicolucci A, Gabellieri E; ENSURE Study Group. Candido R, et al. Among authors: larosa m. Diabetes Ther. 2023 Jan;14(1):77-92. doi: 10.1007/s13300-022-01328-7. Epub 2022 Nov 14. Diabetes Ther. 2023. PMID: 36376644 Free PMC article.
Corrigendum to Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins > Nutr Metab Cardiovasc Dis. 2022 Sep;32(9):2255-2263.
Buzzetti R, Fadini GP, Nicolucci A, Larosa M, Rossi MC, Cucinotta D; RESTORE-2 Study Group. Buzzetti R, et al. Among authors: larosa m. Nutr Metab Cardiovasc Dis. 2023 Apr;33(4):920-921. doi: 10.1016/j.numecd.2023.02.006. Epub 2023 Mar 21. Nutr Metab Cardiovasc Dis. 2023. PMID: 36948942 No abstract available.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Among authors: larosa m. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
121 results